Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Intensive chemotherapy offers pluses, minuses in advanced endometrial cancer


Complex chemotherapy cocktails offer about one extra month of life to patients with end-stage endometrial cancer but also can result in severe, possibly fatal, side effects, according to the first systematic review of studies addressing the topic.

“ The best drug treatment for women with advanced cancer of the womb is still not clear,” concludes the review, led by Dr. Caroline Humber of Walsgrave Hospital in England.

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The authors identified 11 randomized controlled trials with 2,288 participants. All compared one or more of the commonly used chemotherapy agents with an alternative drug, combination, or dosing schedule.

Six of the trials compared combinations of three or more drugs to simpler regimens. A combined analysis for all 1,135 women showed that the more intense treatments did a better job of controlling tumor growth, yet no drug combination stood out as superior.

But increasing the number of chemotherapy drugs also increased the likelihood of serious damage to the heart, kidneys, nerves, digestive system, blood cells and other body systems. The studies reported as many as 12 possible treatment-related deaths.
Among the drugs compared were paclitaxel, cisplatin, doxorubicin and 5-fluoracil.
Dr. Ira Horowitz, a gynecologic oncologist at Emory University, says that patients with advanced endometrial cancer are generally older and often have multiple health problems related to obesity and diabetes.

“ When you’re 60, 70, 80 years old with advanced endometrial cancer, it’s much more difficult to tolerate the drugs and the side effects. …They may not get that payback for what it’s going to take out of them.”

The review authors had set out to answer the kinds of questions that patients ask when considering treatment options, says Humber. “They ask ‘Will this make me live longer? Will this make my cancer stay away for longer? Will it make me feel better? Will it help my symptoms?’”

These questions remain largely unanswered. The authors could locate no studies that compared chemotherapy for advanced endometrial cancer with other options such as hormone therapy, comfort care or no treatment. Moreover, none of the studies examined symptom control and quality of life issues.

“ It would be nice to know what the quality of life was,” says Humber. “In other types of cancer that we treat, for example lung cancer, we do see very small gains in survival but absolutely enormous gains in quality of life reported by patients. ... But we don’t know that for this condition.”

The report says that collection of such patient-reported data should be a priority in future research. “ What ought to come out of this is that we need to continue to recruit patients into well-designed trials,” says Humber. Yet, because of the relative rarity of the condition and the frequency of co-existing health problems, recruiting enough participants for a thorough study can be a long, slow process.

For example, Dr. David Scott Miller — a professor of obstetrics and gynecology at the University of Texas Southwestern Medical Center — is leading a government-funded study that is seeking 900 participants. Miller and his colleagues will compare survival rates, quality of life and side effects of two widely used drug combinations. They aim to complete the study within five years.

“ We hope [the Cochrane findings] might spur people to participate,” says Miller. “There are about 6,000 or 7,000 women who are likely to die of endometrial cancer in the United States annually. Those patients would all be appropriate candidates for chemotherapy and for our trial.”

Because early-stage endometrial cancer can usually be cured by surgical removal of the uterus, advanced stages are relatively rare. About 50,000 deaths occur each year worldwide. The condition is most common in North America and Europe, and risk factors include obesity, hypertension, diabetes and hormone replacement therapy.

Humber C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. The Cochrane Database of Systematic Reviews 2005, Issue 3.

The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions.

Carolyn Humber | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>